Business Standard

Covid-19 crisis: Bharat Biotech's vaccine gets nod for human trials

The SARS-CoV-2 strain was isolated at National Institute of Virology (Pune), an institute under the ICMR, and transferred to Bharat Biotech.

bharat biotech, vaccine, coronavirus, covid-19, pharma, drugs, medicine
Premium

Bharat Biotech has a biosafety level-3 plant in Hyderabad.

Sohini Das Mumbai
Bharat Biotech’s Covid vaccine candidate Covaxin is set to undergo human clinical trials in July. It was developed at the firm’s Genome Valley plant in Hyderabad, in collaboration with the Indian Council of Medical Research (ICMR).

On Monday, the Hyderabad-based firm said the Drug Controller General of India gave the green light for phase-1 and phase-2 human clinical trials of the indigenously developed drug, following submission of results generated from pre-clinical (animal) studies. These were meant to demonstrate safety and immune response.

The SARS-CoV-2 strain was isolated at National Institute of Virology (Pune), an institute under the ICMR, and transferred

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 30 2020 | 2:39 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com